17a-Hydroxypregnenolone
Based on 2 publication(s) in Google Scholar
17a-Hydroxypregnenolone (17-OHP5) is a metabolite of Pregnenolone (HY-B0151) and a precursor in the biosynthesis of Dehydroepiandrosterone (HY-14650). 17a-Hydroxypregnenolone is a substrate for the enzyme 3β-hydroxysteroid dehydrogenase (3β-HSD).
For research use only. We do not sell to patients.
- Purity: 99.61%
- CAS No.: 387-79-1
- Formula: C21H32O3
- Molecular Weight:332.48
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) 17a-Hydroxypregnenolone
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
17a-Hydroxypregnenolone is formed from pregnenolone by cytochrome P450 (CYP) isoform CYP17A1 hydroxylase activity and then converted to dehydroepiandrosterone by CYP17A1-mediated 17,20-lyase activity[1].
17a-Hydroxypregnenolone is elevated in patients with type II 3β-hydroxysteroid dehydrogenase deficiency, a form of congenital adrenal hyperplasia[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 387-79-1
-
Appearance Solid
-
Molecular Weight 332.48
-
Formula C21H32O3
-
Color White to off-white
-
SMILES
CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O
-
Synonyms
17-OHP5
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
2025 Mar 11;15(1):8409. PMID: 40069295 -
Curr Res Toxicol
Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays. [Abstract]2023 Aug 14:5:100119. PMID: 37637492
Solvent & Solubility
DMSO : 8.33 mg/mL (25.05 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.83 mg/mL (2.50 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.83 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (2.50 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (796 KB)
- English - EN (796 KB)
- Français - FR (796 KB)
- Deutsch - DE (796 KB)
- Norwegian - NO (796 KB)
- Español - ES (796 KB)
- Swedish - SV (796 KB)
- Italian - IT (796 KB)
- Portuguese - PT (796 KB)
-
Handling Instructions (2659 KB)
References
[1]. Petrunak EM, et al. Structures of human steroidogenic cytochrome P450 17A1 with substrates. J Biol Chem. 2014 Nov 21;289(47):32952-64. [Content Brief]
[2]. Fiet J, et al. Plasma 17-OH pregnenolone: comparison of a time-resolved fluoroimmunoassay using a new tracer 17-OH pregnenolone-3-oxyacetyl-biotine with a radioimmunoassay using 125I 17-OH pregnenolone-3-hemisuccinate-histamine. Steroids. 2001 Feb;66(2):81-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0077 mL | 15.0385 mL | 30.0770 mL | 75.1925 mL |
| 5 mM | 0.6015 mL | 3.0077 mL | 6.0154 mL | 15.0385 mL | |
| 10 mM | 0.3008 mL | 1.5038 mL | 3.0077 mL | 7.5192 mL | |
| 15 mM | 0.2005 mL | 1.0026 mL | 2.0051 mL | 5.0128 mL | |
| 20 mM | 0.1504 mL | 0.7519 mL | 1.5038 mL | 3.7596 mL | |
| 25 mM | 0.1203 mL | 0.6015 mL | 1.2031 mL | 3.0077 mL |